Dimensional Fund Advisors LP boosted its holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 259.2% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 554,802 shares of the company's stock after buying an additional 400,336 shares during the quarter. Dimensional Fund Advisors LP owned 0.94% of Zevra Therapeutics worth $5,168,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Zevra Therapeutics by 15.2% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company's stock valued at $36,720,000 after acquiring an additional 550,000 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Zevra Therapeutics by 4.4% in the third quarter. Vanguard Group Inc. now owns 3,083,362 shares of the company's stock worth $29,323,000 after acquiring an additional 130,676 shares during the period. Nantahala Capital Management LLC raised its holdings in shares of Zevra Therapeutics by 34.0% during the third quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company's stock valued at $18,753,000 after purchasing an additional 500,000 shares during the last quarter. Rubric Capital Management LP raised its holdings in shares of Zevra Therapeutics by 60.8% during the second quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company's stock valued at $17,253,000 after purchasing an additional 740,584 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Zevra Therapeutics by 3.9% during the fourth quarter. State Street Corp now owns 1,482,956 shares of the company's stock valued at $13,287,000 after purchasing an additional 55,665 shares during the last quarter. Institutional investors own 35.03% of the company's stock.
Zevra Therapeutics Stock Performance
NASDAQ ZVRA opened at $11.34 on Wednesday. The business's fifty day moving average is $12.33 and its 200 day moving average is $10.62. Zevra Therapeutics, Inc. has a fifty-two week low of $7.16 and a fifty-two week high of $15.03. The company has a market capitalization of $673.37 million, a PE ratio of 12.33 and a beta of 0.91.
Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.11 by $0.14. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%.The firm had revenue of $39.66 million for the quarter, compared to the consensus estimate of $33.88 million. On average, sell-side analysts forecast that Zevra Therapeutics, Inc. will post 0.6 EPS for the current year.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on ZVRA. Maxim Group raised their target price on shares of Zevra Therapeutics from $25.00 to $35.00 and gave the stock a "buy" rating in a report on Wednesday, June 10th. Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a research note on Thursday, August 6th. Wall Street Zen raised Zevra Therapeutics from a "hold" rating to a "buy" rating in a report on Sunday, July 12th. HC Wainwright reissued a "buy" rating and set a $26.00 price target on shares of Zevra Therapeutics in a report on Tuesday, June 23rd. Finally, Guggenheim dropped their price target on Zevra Therapeutics from $24.00 to $23.00 and set a "buy" rating on the stock in a research note on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, Zevra Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $27.14.
Check Out Our Latest Report on Zevra Therapeutics
Zevra Therapeutics Profile
(
Free Report)
Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Zevra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.
While Zevra Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
